FLUOROURACILE ACCORD 50 mg/ml
Sponsors
Institut Gustave Roussy, Fondation Franc.Cancerologie Digestive, Institut De Cancerologie De L Ouest, Centre Hospitalier Universitaire De Bordeaux, Oncopole Claudius Regaud
Conditions
Adult patients with intermediate low or mid rectal adenocarcinoma to be treated with total neoadjuvant therapy (TNT) potentially eligible for rectal preservation.Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)First-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinomasRectal cancerRecurrent rectal cancer after local excisionResectable Gastric Cancercolorectal cancergastric and gastro-oesophageal junction adenocarcinomas
Phase 2
PHASE II study evaluating the benefit of Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
RecruitingCTIS2024-515344-23-00
Start: 2021-06-17Target: 103Updated: 2025-03-24
Reduction in the number of chemotherapy cycles in combination with Pembrolizumab in first-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinomas
RecruitingCTIS2024-514875-16-00
Start: 2024-10-21Target: 86Updated: 2025-10-30
Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A phase II study (GASPAR)
CompletedCTIS2024-516299-13-00
Start: 2024-09-06End: 2025-11-27Target: 68Updated: 2024-09-05
ENGIC - 01 COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a doublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated colorectal adenocarcinoma
RecruitingCTIS2024-514030-20-00
Start: 2025-08-29Target: 37Updated: 2026-01-13
Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative setting for resectable stage cT2-T4a or N+ gastric and GEJ adenocarcinoma overexpressing FGFR2b (BEMAFLOT)
CompletedCTIS2024-514078-29-00
End: 2025-11-07Target: 49Updated: 2025-10-02
Risk-adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with FOLFIRINOX
FRENCH26 – PRODIGE93 - PANACHE02 Trial
RecruitingCTIS2024-519048-33-00
Start: 2025-11-25Target: 390Updated: 2025-05-28
Phase 3
Multicenter randomized Phase III trial evaluating contact X-ray brachytherapy for rectal preservation in intermediate substage rectal adenocarcinoma (TRESOR)
RecruitingCTIS2023-506885-30-00
Start: 2024-03-26Target: 212Updated: 2025-03-11
A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment for locally recurrent rectal cancer (GRECCAR – PRODIGE – FRENCH) - GRECCAR 15
Active, not recruitingCTIS2024-514705-62-00
Start: 2019-07-08Target: 186Updated: 2024-07-04
Neoadjuvant Chemotherapy for Obstructive Colon cancER first Treated by cOlostomy : A randomized phase III trial - COnCERTO (French 01-18) 2019/0407/HP
RecruitingCTIS2024-516456-17-00
Start: 2024-05-07Target: 232Updated: 2025-07-17
GCO-003 TARLANEC A randomized phase III trial study comparing tarlatamab with standard of care chemotherapy in patients with pre-treated advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas
Not yet recruitingCTIS2024-515948-23-00
Target: 129Updated: 2025-09-02